argenx N.V.

“Pipeline in a pill”-style drug development will be on display in April, when more than half of the user fee goal dates are for new indications on sometimes sprawling labels, as well as one novel biol

Despite struggling with the financial burden, Chinese firm RemeGen is pulling out all the stops for its ongoing global Phase III RemeMG study to repeat the positive safety and efficacy outcomes from

Roivant subsidiary Immunovant announced positive Phase III data for its neonatal fragment crystallizable receptor (FcRn) inhibitor batoclimab in myasthenia gravis (MG), but a key piece of the update i

Amgen believes it can muscle in on the generalized myasthenia gravis (gMG) market with Uplizna (inebilizumab-cdon), to challenge market leader Argenx’s Vyvgart and other rivals, although analysts are